Hello Dr. Young,

I initially posted this query at your blog site. This is a question that many of us in the NMO Community are concerned about. Input please.


I have just completed reading your article and wanted to comment, and ask a question. Since the mortality rate for NMO is high in itself (Some estimates put it at roughly 33% within the first five years.) and since the mortality rate for myeloablative regimens is now approaching 1%, it would appear that the benefit of the procedure for NMO patients far outweighs the risk.

That being said, because NMO is B Cell mediated, and the NMO IgG autoimmune antibody *appears* to be a pathological one, would it not be logical to assume that at some point the patients body would once again begin to produce the NMO IgG?

Thank you,